Abiomed (ABMD) Tops Q3 EPS by 16c; Raises Low End of FY Revenues Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Abiomed Announces Record Revenue of $261 Million, up 13% Year Over Year
February 3, 2022 7:00 AM ESTIncreasing Low End of Guidance: $1,025 Million - $1,030 Million, up 21% - 22%
DANVERS, Mass.--(BUSINESS WIRE)-- ABIOMED, Inc. (NASDAQ: ABMD), a leading provider of breakthrough heart support technologies, today announced financial results for the quarter ended December 31, 2021.
Q3 financial summary and operational highlights:
Revenue for the quarter totaled $261 million, an increase of 13% compared to $232 million during the same period of the prior fiscal year. In constant currency,* revenue increased 14% compared to the same period of the prior fiscal year. Worldwide Impella®... More